Generic Viread Availability
Viread is a brand name of tenofovir, approved by the FDA in the following formulation(s):
VIREAD (tenofovir disoproxil fumarate - powder; oral)
-
Manufacturer: GILEAD SCIENCES INC
Approval date: January 18, 2012
Strength(s): 40MG/SCOOPFUL [RLD]
VIREAD (tenofovir disoproxil fumarate - tablet; oral)
-
Manufacturer: GILEAD SCIENCES INC
Approval date: October 26, 2001
Strength(s): 300MG [RLD] -
Manufacturer: GILEAD SCIENCES INC
Approval date: January 18, 2012
Strength(s): 150MG, 200MG, 250MG
Has a generic version of Viread been approved?
No. There is currently no therapeutically equivalent version of Viread available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viread. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Patent 5,922,695
Issued: July 13, 1999
Inventor(s): Arimilli; Murty N. & Cundy; Kenneth C. & Dougherty; Joseph P. & Kim; Choung U. & Oliyai; Reza & Stella; Valentino J.
Assignee(s): Gilead Sciences, Inc.
Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy or prophylaxis. Embodiments are particularly useful when administered orally.Patent expiration dates:- July 25, 2017✓✓
- July 25, 2017✓✓
- July 25, 2017✓✓
- July 25, 2017✓✓
- July 25, 2017✓✓
- January 25, 2018✓
- July 25, 2017
-
Nucleotide analog composition and synthesis method
Patent 5,935,946
Issued: August 10, 1999
Inventor(s): Munger, Jr.; John D. & Rohloff; John C. & Schultze; Lisa M.
Assignee(s): Gilead Sciences, Inc.
The invention provides a composition comprising bis(POC)PMPA and fumaric acid (1:1). The composition is useful as an intermediate for the preparation of antiviral compounds, or is useful for administration to patients for antiviral therapy or prophylaxis. The composition is particularly useful when administered orally. The invention also provides methods to make PMPA and intermediates in PMPA synthesis. Embodiments include lithium t-butoxide, 9-(2-hydroxypropyl) adenine and diethyl p-toluenesulfonylmethoxyphosphonate in an organic solvent such as DMF. The reaction results in diethyl PMPA preparations containing an improved by-product profile compared to diethyl PMPA made by prior methods.Patent expiration dates:- July 25, 2017✓✓✓
- July 25, 2017✓✓✓
- July 25, 2017✓✓✓
- July 25, 2017✓✓✓
- July 25, 2017✓✓✓
- January 25, 2018✓
- July 25, 2017
-
Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Patent 5,977,089
Issued: November 2, 1999
Inventor(s): Arimilli; Murty N. & Cundy; Kenneth C. & Dougherty; Joseph P. & Kim; Choung U. & Oliyai; Reza & Stella; Valentino J.
Assignee(s): Gilead Sciences, Inc.
Compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure --OC(R.sup.2).sub.2 OC(O)X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C.sub.12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy or prophylaxis. Embodiments are particularly useful when administered orally.Patent expiration dates:- July 25, 2017✓✓✓
- July 25, 2017✓✓✓
- July 25, 2017✓✓✓
- July 25, 2017✓✓✓
- July 25, 2017✓✓✓
- January 25, 2018✓
- July 25, 2017
-
Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Patent 6,043,230
Issued: March 28, 2000
Inventor(s): Arimilli; Murty N. & Cundy; Kenneth C. & Dougherty; Joseph P. & Kim; Choung U. & Oliyai; Reza & Stella; Valentino J.
Assignee(s): Gilead Sciences, Inc.
Novel compounds are provided that comprise esters of antiviral phosphonomethoxy nucleotide analogs with carbonates and/or carbamates having the structure -OC(R.sup.2).sub.2 OC(O) X(R).sub.a, wherein R.sup.2 independently is H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, azido, nitro or OR.sup.3 in which R.sup.3 is C.sub.1 -C12 alkyl; X is N or O; R is independently H, C.sub.1 -C.sub.12 alkyl, aryl, alkenyl, alkynyl, alkyenylaryl, alkynylaryl, alkaryl, arylalkynyl, arylalkenyl or arylalkyl which is unsubstituted or is substituted with halo, axido, nitro, --O--, --N.dbd., --NR.sup.4 --, --N(R.sup.4).sub.2 -- or OR.sup.3, R.sup.4 independently is --H or C.sub.1 -C.sub.8 alkyl, provided that at least one R is not H; and a is 1 or 2, with the proviso that when a is 2 and X is N, (a) two R groups can be taken together to form a carbocycle or oxygen-containing heterocycle, or (b) one R additionally can be OR.sup.3. The compounds are useful as intermediates for the preparation of antiviral compounds or oligonucleotides, or are useful for administration directly to patients for antiviral therapy or prophylaxis. Embodiments are particularly useful when administered orally.Patent expiration dates:- July 25, 2017✓
- July 25, 2017✓
- July 25, 2017✓
- July 25, 2017✓
- July 25, 2017✓
- January 25, 2018✓
- July 25, 2017
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- March 24, 2013 - NEW PATIENT POPULATION
- September 24, 2013 - PEDIATRIC EXCLUSIVITY
- October 1, 2013 - INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
- April 1, 2014 - PEDIATRIC EXCLUSIVITY
- January 18, 2015 - NEW DOSAGE FORM
- January 18, 2015 - NEW PATIENT POPULATION
- July 18, 2015 - PEDIATRIC EXCLUSIVITY
- August 16, 2015 - NEW PATIENT POPULATION
- March 24, 2017 - ORPHAN DRUG EXCLUSIVITY
- September 24, 2017 - PEDIATRIC EXCLUSIVITY
See also...
- Viread Consumer Information (Drugs.com)
- Viread Consumer Information (Wolters Kluwer)
- Viread powder Consumer Information (Wolters Kluwer)
- Viread Consumer Information (Cerner Multum)
- Viread Advanced Consumer Information (Micromedex)
- Viread AHFS DI Monographs (ASHP)
- Tenofovir Consumer Information (Wolters Kluwer)
- Tenofovir powder Consumer Information (Wolters Kluwer)
- Tenofovir Consumer Information (Cerner Multum)
- Tenofovir Advanced Consumer Information (Micromedex)
- Tenofovir Disoproxil Fumarate AHFS DI Monographs (ASHP)
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
